HSP60 Inhibitor Compounds for Selective Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments targeting molecular chaperones like HSP90 and HSP70 have shown toxicity to non-cancerous cells and limited efficacy, necessitating the development of inhibitors for other chaperones such as HSP60 to improve treatment outcomes.
Innovation Solution
Development of antibacterial and antiparasitic compounds with specific chemical structures to inhibit HSP60 chaperonin activity, shown to be effective in treating cancer cells while minimizing harm to non-cancerous cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If HSP90 and HSP70 inhibitors are used to treat cancer, then cancer cell proliferation is inhibited, but toxicity to non-cancerous cells increases and heat-shock response is upregulated
Solution Approach 1:
The patent changes the target parameter from HSP90/HSP70 to HSP60 chaperonin, a different molecular weight and family of heat shock protein. This parameter change in target selection allows inhibition of cancer cell proliferation while avoiding the toxicity and heat-shock response upregulation associated with HSP90/HSP70 inhibitors, as HSP60 has distinct functional roles and tissue distribution
Solution Approach 2:
The patent segments the HSP inhibitor development by focusing specifically on HSP60 chaperonin as a separate target family from HSP90 and HSP70. This segmentation allows for selective inhibition of HSP60 without affecting HSP90/HSP70 systems, thereby achieving anticancer efficacy while avoiding the adverse effects associated with those other HSP targets
2Reliability
If HSP90 inhibitors are used to treat cancer, then cancer cell survival is reduced, but expression levels of other HSPs like HSP70 increase to compensate
Solution Approach 1:
The patent changes the inhibition target from HSP90 to HSP60 chaperonin, a different parameter in the HSP family with distinct client proteins and functional pathways. This prevents the compensatory upregulation of HSP70 and other HSPs that occurs with HSP90 inhibition, as HSP60 operates in separate cellular compartments and protein folding pathways
Solution Approach 2:
The patent uses HSP60 chaperonin as an intermediary target that can mediate cancer cell death without triggering the compensatory heat-shock response pathway activated by HSP90/HSP70 inhibition. HSP60 serves as an alternative mediator of protein homeostasis disruption that does not activate the same feedback loops
Data Source
AI summary
The present disclosure relates to HSP60 inhibitor compounds, pharmaceutical compositions containing the compounds, and methods of using such compounds to treat cancer.